Article Information
History
- January 23, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Jixin Wang1,
- Wen Yu2,
- Rachel D’Anna1,
- Anna Przybyla3,
- Matt Wilson4,
- Matthew Sung3,
- John Bullen5,
- Elaine Hurt5,
- Gina DAngelo6,
- Ben Sidders7,
- Zhongwu Lai8 and
- Wenyan Zhong9,*
- 1Oncology Data Science, AstraZeneca, Gaithersburg, MD
- 2Data Science and AI, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD
- 3Immune-oncology Discovery, AstraZeneca, Cambridge, UK
- 4Early TDE Discovery, AstraZeneca, Cambridge, UK
- 5Early TTD Discovery, AstraZeneca, Cambridge, UK
- 6Late Oncology Statistics, Oncology R&D, AstraZeneca, Gaithersburg, MD
- 7Oncology Data Science, Oncology R&D, AstraZeneca, Cambridge, UK
- 8Oncology Data Science, Oncology R&D, AstraZeneca, Waltham, MA
- 9Oncology Data Science, Oncology R&D, AstraZeneca, New York, NY
- ↵*Corresponding author:
Wenyan Zhong, AstraZeneca, One MedImmune Way, Gaithersburg, MD 20878, USA, Phone: (301) 398-4209, Fax: (301) 398-9000, E-mail: wenyan.zhong{at}astrazeneca.com
Posted January 23, 2023.
Pan-cancer Proteomics Analysis to Identify Tumor-Enriched and Highly Expressed Cell Surface Antigens as Potential Targets for Cancer Therapeutics
